Fri.Mar 15, 2024

article thumbnail

With Pfizer struggling in 2023, CEO Bourla hit with 35% pay cut to $21.6M

Fierce Pharma

Pfizer knew 2023 was going to be a challenging year of transition. But even the drugmaker was surprised by the plummeting demand for its COVID-19 products, missing badly on its 2023 guidance. | After a difficult year for Pfizer, in which its share price fell by 44%, CEO Albert Bourla’s compensation fell by 35% from $33 million in 2022 to $21.6 million in 2023.

363
363
article thumbnail

A Startup’s Flexibility With ADC Cancer Drugs Attracts €128M for Clinical Trials

MedCity News

Tubulis’s next-generation ADC cancer drugs are designed to overcome limitations of currently available therapies in this drug class. The new financing will support clinical trial plans, but first, preclinical proof-of-concept data will be presented during the American Association for Cancer Research annual meeting.

Biopharma 112
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Despite early death concerns, FDA advisers back J&J and Legend's Carvykti for earlier myeloma

Fierce Pharma

Even though the BCMA CAR-T therapy Carvykti showed a potential problem of early patient deaths in a trial, experts on the FDA’s Oncologic Drugs Advisory Committee (ODAC) still believe that the drug | Even though the BCMA CAR-T therapy Carvykti showed a potential problem of early patient deaths in a trial, experts on the FDA’s Oncologic Drugs Advisory Committee still believe that the drug’s long-term benefits outweigh its risks.

FDA 317
article thumbnail

The Case for Domestic Sourcing to Establish Reliable Pharmaceutical Supply Chains in the United States

Pharmaceutical Commerce

Reliance on foreign imports means that disruptions in the supply chain can profoundly impact the ability of individuals in the United States to get access to the medications they need.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Novartis lays out $256M for antibody plant expansion in Singapore, plots 100 hires

Fierce Pharma

Over the years, Singapore has attracted a suite of biopharma majors, and Novartis is no exception. | Novartis broke ground on a $256 million expansion of its biopharmaceutical production facility in Singapore. The project will introduce digitalization and automation at the site in a bid to boost manufacturing productivity and to help upskill the company’s workforce.

Biopharma 309
article thumbnail

The Power of Co-Creation in Cultivating Authenticity

Eversana Intouch

In a recent article published by Med Ad News and PharmaLive.com , Hattie Stearns, Senior Director of Experience DesignOps, provides five key takeaways she observed as a brand and design lead at SXSW 2024. In the article, Hattie expands on each takeaway and highlights the responsibility we have as marketers to co-create and cultivate authentically. Art meets tech for healing and community Brands getting real Designing with heart and inclusivity Learning through stories AI with a human touch “Co-c

Marketing 103

More Trending

article thumbnail

After Amylyx drug failure, what’s next for ALS?

PharmaVoice

The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

Marketing 120
article thumbnail

BioDesign: Accelerating the Momentum of Bioconjugate Therapeutics

Fierce Pharma

Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities. | Antibody-drug conjugates are a promising biopharma modality but specialized expertise is instrumental for successfully bringing drugs to the clinic.

Biopharma 228
article thumbnail

Hackensack Meridian Health CEO: These 4 Priorities Should Guide AI Strategy

MedCity News

During a keynote address at HIMSS, Hackensack Meridian Health CEO Robert Garrett outlined four priorities that should guide healthcare organizations’ AI strategies. He said that healthcare leaders need to take care to ensure their AI efforts seek to address one if not all of these.

article thumbnail

Merck's Keytruda excels in cervical cancer trial, showing an ability to extend lives. Will a broader FDA approval follow?

Fierce Pharma

Merck's Keytruda excels in cervical cancer trial, showing an ability to extend lives. Will a broader FDA approval follow?

FDA 144
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Mycoplasma testing market expected to value nearly $2 million by 2031

European Pharmaceutical Review

According to research published by Coherent Market Insights, the global mycoplasma testing market is anticipated to reach $1,907.6 million by 2031. The market is set to witness a compound annual growth rate (CAGR) of 9.7 percent during the forecast period, the report predicted. What is driving and limiting growth in the market? Specifically, technology innovations such as sequencing technology, supported by “strong government funding for biomedical research” in the US has driven rapid developmen

article thumbnail

EuroAPI's troubles mount as audit reveals manufacturing lapses in Italy, spurring 2024 guidance suspension

Fierce Pharma

Beleaguered Sanofi spinout EuroAPI can’t seem to catch a break. | Beleaguered Sanofi spinout EuroAPI can’t seem to catch a break. After reporting ballooning losses and a four-year restructuring plan last month, the company revealed Thursday that manufacturing lapses at an Italian plant have temporarily derailed its guidance for the year.

article thumbnail

Analytical technique may advance medical cannabis quality control

European Pharmaceutical Review

Researchers have proposed an advanced analytical technology that can rapidly classify medical cannabis plants at production sites. Using the analytical technique, the plants can be classified “by chemotype using hyperspectral imaging and machine learning (ML),” Markel San Nicolas, researcher in the UPV/EHU’s IBeA group of the University of the Basque Country, and first author of the corresponding research paper explained.

Medical 97
article thumbnail

Healthee heads latest crop of digital health financings

pharmaphorum

Our latest round-up of funding rounds in the digital health category features updates from Healthee, Aktiia, Moxe Health, Eleanor Health, Tava Health, BrainCheck, and Redi Health.

99
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

Gonorrhea, Chlamydia and Syphilis Rates Are Exploding. Here’s How AI Can Help.

MedCity News

The emergence of artificial intelligence (AI) offers a glimmer of hope in the fight against STDs and has the power to revolutionize the landscape of STD detection, treatment, and prevention.

102
102
article thumbnail

ALS body takes digital approach to clinical trials access

pharmaphorum

The ALS Association is partnering with myTomorrows to connect patients and physicians with clinical trials using a digital platform.

article thumbnail

With FDA greenlight, BMS Breyanzi brings CAR-T cell therapy to CLL and SLL

Pharmaceutical Technology

Amidst the many BTK inhibitors, Breyanzi will be the first and only CAR-T cell therapy available for the treatment of CLL and SLL.

FDA 105
article thumbnail

Future medicine makers will get VR training at new UK centre

pharmaphorum

Consortium led by Birmingham University unveils a centre of excellence for medicines manufacturing training using VR, to answer a UK skills shortage.

Training 103
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Three different ways AI will shape the future of the pharma industry

Impetus Digital

This is a guest article and does not necessarily reflect the views and values of Impetus Digital. When it comes to artificial intelligence (AI), it feels like no industry has been left untouched. Even those that might not feel like a natural fit for computers are being shaped and influenced by this technology, with artists and writers utilizing it in new ways.

Pharma 87
article thumbnail

Solera Health, Aon Join Forces to Simplify Employee Healthcare

MedCity News

Solera Health and Aon are collaborating to help employers manage point solution fatigue, engage members and measure ROI.

article thumbnail

Madrigal Pharma is first over the MASH finish line

pharmaphorum

Madrigal Pharma is first pharma company to get FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH)

Pharma 101
article thumbnail

Anocca signs licensing deal for EmendoBio’s gene-editing tech

Pharmaceutical Technology

Anocca has entered a licensing agreement with EmendoBio for the use of the latter’s OMNI-A4 nuclease, a gene editing technology.

97
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

Impetus Digital

A version of this article was previously published in the Journal of mHealth. The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1).

article thumbnail

FDA approves Madrigal’s Rezdiffra as the first NASH therapy

Pharmaceutical Technology

Madrigal’s Rezdiffra received an accelerated approval as a treatment for noncirrhotic NASH, also known as MASH.

FDA 98
article thumbnail

Getting the Lay of the Land After a Banner Year for Biosimilars

Pharmaceutical Commerce

Biosimilars market experiences massive growth, but regulatory and adoption challenges remain.

Marketing 105
article thumbnail

Geron leaps as ODAC backs its MDS drug imetelstat

pharmaphorum

Geron rockets after FDA advisory committee backs imetelstat as a treatment for transfusion-dependent myelodysplastic syndromes

FDA 93
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

NIHR reveals phase 1/2 trial to evaluate an investigational vaccine for mpox in the UK

PharmaTimes

More than 3,700 cases of mpox have been identified in the UK since May 2022

article thumbnail

Pharma Pulse 3/15/24: Elranatamab Maintains or Improves Symptoms of Multiple Myeloma Patients, AI Assistant for Security Products & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 105
article thumbnail

NHS to roll out AI to improve waiting times and reduce missed appointments

PharmaTimes

Every year, missed hospital appointments are estimated to cost the NHS £1.

Medical 88
article thumbnail

Digitalization of QbD Risk Assessments

PharmaTech

Quality-by-design risk assessment workflows can be laborious and have limited capacity to connect with vast volumes of prior knowledge generated by organizations. Their digital transformation can improve efficiency, reduce human errors, and facilitate integration within a much broader digital ecosystem.

52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A